Cefadroxil 250mg Tablet Franchise in Ahmedabad

Oral Antibiotic Medicine Supplier in Bangalore

Bacterial Infection Tablet Distributor in Hyderabad

Skin & Respiratory Infection Tablet Franchise Opportunity in Jaipur

Urinary Tract Infection Medicine Stockist in Mumbai
Cefadroxil 250mg Tablet Export & Manufacturing in Chandigarh

Home/Products /cefadroxil-250mg-tablet

Droxifix 250 Tablet

Composition : Cefadroxil (250mg) Tablet

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*10

Price : ₹1/-

Droxifix 250 Tablet contains Cefadroxil 250mg, a broad-spectrum antibiotic effective against bacterial infections of the respiratory tract, urinary system, skin, and soft tissues. It helps in rapid bacterial clearance, reducing symptoms such as fever, inflammation, and discomfort associated with infections.

The formulation ensures reliable absorption and consistent therapeutic action, making it a preferred choice for physicians treating both acute and chronic bacterial infections. It is widely prescribed in general medicine, outpatient care, pediatrics, and hospital settings.

For distributors and resellers, Droxifix 250 Tablet is a high-demand antibiotic product, regularly required in hospitals, clinics, and healthcare facilities. Its universal applicability for common bacterial infections ensures steady sales and recurring demand throughout the year.

Adding Droxifix 250 Tablet to your product portfolio strengthens your antibiotics and infection-care segment, offering opportunities for bulk institutional supply, government tenders, private hospital chains, export markets, and third-party manufacturing. Its essential role in bacterial infection management makes it a profitable and strategically valuable product for any medical distributor.

Read More

About the Product

Droxifix 250 Tablet contains Cefadroxil 250mg, a broad-spectrum antibiotic effective against bacterial infections of the respiratory tract, urinary system, skin, and soft tissues. It helps in rapid bacterial clearance, reducing symptoms such as fever, inflammation, and discomfort associated with infections.

The formulation ensures reliable absorption and consistent therapeutic action, making it a preferred choice for physicians treating both acute and chronic bacterial infections. It is widely prescribed in general medicine, outpatient care, pediatrics, and hospital settings.

For distributors and resellers, Droxifix 250 Tablet is a high-demand antibiotic product, regularly required in hospitals, clinics, and healthcare facilities. Its universal applicability for common bacterial infections ensures steady sales and recurring demand throughout the year.

Adding Droxifix 250 Tablet to your product portfolio strengthens your antibiotics and infection-care segment, offering opportunities for bulk institutional supply, government tenders, private hospital chains, export markets, and third-party manufacturing. Its essential role in bacterial infection management makes it a profitable and strategically valuable product for any medical distributor.

Some patients may experience nausea, vomiting, diarrhea, abdominal discomfort, or mild skin rash. Rarely, severe allergic reactions, liver enzyme abnormalities, or antibiotic-associated colitis may occur.

It is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, and other bacterial infections. It helps relieve symptoms and supports the elimination of pathogenic bacteria.

Use only under medical supervision. Avoid in patients with known hypersensitivity to cephalosporins or penicillins. Complete the full course even if symptoms improve early.

Store the dry syrup in a cool, dry place below 25°C. After reconstitution, store the syrup in the refrigerator and use within the prescribed duration. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation